Page 73 - Read Online

Page 18 of 19 Lin et al. Cancer Drug Resist. 2026;9:14

58. Leduc PR, Wong MS, Ferreira PM, et al. Towards an in vivo biologically inspired nanofactory. Nat Nanotechnol 2007;2:3-7. DOI
PubMed
59. Liu Y, Crowe WN, Wang L, Petty WJ, Habib AA, Zhao D. Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1
blockade for locally advanced lung cancer. Nano Res 2023;16:5300-10. DOI PubMed PMC
60. Sun F, Zhu Q, Li T, et al. Regulating glucose metabolism with prodrug nanoparticles for promoting photoimmunotherapy of pancreatic
cancer. Adv Sci 2021;8:2002746. DOI PubMed PMC
61. Zhang F, Stephan SB, Ene CI, Smith TT, Holland EC, Stephan MT. Nanoparticles that reshape the tumor milieu create a therapeutic
window for effective T-cell therapy in solid malignancies. Cancer Res 2018;78:3718-30. DOI PubMed PMC
62. Lin YX, Wang Y, Ding J, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in
preclinical models. Sci Transl Med 2021;13:eaba9772. DOI PubMed PMC
63. Yu X, Fang C, Zhang K, Su C. Recent advances in nanoparticles-based platforms targeting the PD-1/PD-L1 pathway for cancer
treatment. Pharmaceutics 2022;14:1581. DOI PubMed PMC
64. Jung JY, Ryu HJ, Lee SH, et al. siRNA nanoparticle targeting PD-L1 activates tumor immunity and abrogates pancreatic cancer growth
in humanized preclinical model. Cells 2021;10:2734. DOI PubMed PMC
65. Wu Y, Gu W, Li J, Chen C, Xu ZP. Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity
of tumor-infiltrating lymphocytes. Nanomedicine 2019;14:955-67. DOI PubMed
66. Erel-Akbaba G, Carvalho LA, Tian T, et al. Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy. ACS
Nano 2019;13:4028-40. DOI PubMed PMC
67. Guan X, Lin L, Chen J, et al. Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy. J Control Release
2019;293:104-12. DOI PubMed
68. Yin T, Fan Q, Hu F, et al. Engineered macrophage-membrane-coated nanoparticles with enhanced PD-1 expression induce
immunomodulation for a synergistic and targeted antiglioblastoma activity. Nano Lett 2022;22:6606-14. DOI PubMed
69. Younis M, Wu Y, Fang Q, Shan H, Huang X. Synergistic therapeutic antitumor effect of PD-1 blockade cellular vesicles in combination
with Iguratimod and Rhodium nanoparticles. J Colloid Interface Sci 2023;649:929-42. DOI PubMed
70. Xiao Z, Su Z, Han S, Huang J, Lin L, Shuai X. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver
NF-κB inhibitor for antitumor immunotherapy. Sci Adv 2020;6:eaay7785. DOI PubMed PMC
71. Shi Y, Lammers T. Combining nanomedicine and immunotherapy. Acc Chem Res 2019;52:1543-54. DOI PubMed PMC
72. Chen IX, Chauhan VP, Posada J, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves
immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A 2019;116:4558-66. DOI PubMed PMC
73. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c
mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol
2009;9:900-9. DOI PubMed
74. Kong M, Tang J, Qiao Q, et al. Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and
enhancing antitumor efficiency. Theranostics 2017;7:3276-92. DOI PubMed PMC
75. Wang D, Wang T, Yu H, et al. Engineering nanoparticles to locally activate T cells in the tumor microenvironment. Sci Immunol
2019;4:eaau6584. DOI PubMed
76. Joyce P, Allen CJ, Alonso MJ, et al. A translational framework to DELIVER nanomedicines to the clinic. Nat Nanotechnol
2024;19:1597-611. DOI PubMed
77. Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and
future prospects. Nat Rev Clin Oncol 2023;20:739-54. DOI PubMed
78. Ikeda-Imafuku M, Wang LL, Rodrigues D, Shaha S, Zhao Z, Mitragotri S. Strategies to improve the EPR effect: a mechanistic
perspective and clinical translation. J Control Release 2022;345:512-36. DOI PubMed
79. Cooley MB, Wegierak D, Perera R, et al. Assessing therapeutic nanoparticle accumulation in tumors using nanobubble-based
contrast-enhanced ultrasound imaging. ACS Nano 2024;18:33181-96. DOI PubMed PMC
80. Chen BM, Cheng TL, Roffler SR. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene
glycol antibodies. ACS Nano 2021;15:14022-48. DOI PubMed
81. Estapé Senti M, de Jongh CA, Dijkxhoorn K, et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based
nanoparticles via complement. J Control Release 2022;341:475-86. DOI PubMed
82. Szebeni J, Storm G, Ljubimova JY, et al. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to
mRNA-based SARS-CoV-2 vaccines. Nat Nanotechnol 2022;17:337-46. DOI PubMed
83. Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug
Discov 2024;23:281-300. DOI PubMed
66